Boston Scientific is a global medical device company founded in 1979 by John Abele and Pete Nicholas in Watertown, Massachusetts, initially to acquire Medi-Tech, a maker of steerable catheters. The company helped establish the field of less-invasive medicine, developing devices that treat disease through small openings in the body rather than open surgery. Headquartered in Marlborough, Massachusetts, Boston Scientific operates across cardiovascular and MedSurg divisions. Its cardiology portfolio includes drug-eluting coronary stents, the WATCHMAN left atrial appendage closure device for stroke risk reduction in atrial fibrillation patients, and the FARAPULSE pulsed field ablation system for treating heart rhythm disorders. Other major franchises include endoscopy devices for gastrointestinal procedures, urology products such as kidney stone management systems and the SpaceOAR hydrogel, neuromodulation implants for chronic pain and Parkinson's disease, and interventional oncology and peripheral vascular products. The company has grown substantially through acquisitions, including Guidant's cardiac rhythm management business in 2006, BTG, and Axonics. Boston Scientific reports annual revenue above 14 billion US dollars, employs roughly 48,000 people, and sells products in over 100 countries, with manufacturing and R&D sites across the Americas, Europe, and Asia. It is a component of the S&P 500 and competes primarily with Medtronic, Abbott, and Johnson & Johnson MedTech in the cardiovascular and surgical device markets.
bostonscientific.com/ →